Eli Lilly's experimental drug, retatrutide, showed strong results in a late-stage trial, helping patients lose nearly 29% of ...

The drugmaker is betting big on retatrutide as the next pillar of its obesity portfolio after its weight loss injection ...

Step aside, semaglutide—retatrutide is showing the most impressive weight loss results of any obesity drug to date.

Aching hips, sore knees, and general joint pain are often wrongly assumed to be an inevitable part of life that we simply ...

Discover why Eli Lilly and Company's retatrutide weight loss breakthrough positions LLY as a leader in obesity therapeutics.

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much ...

A novel triple receptor agonist conferred weight loss of up to 28.7% at 68 weeks and reductions in pain for adults with ...

Lilly reports Phase 3 data showing retatrutide delivered substantial weight loss, reduced knee pain, and improved ...

Lilly’s closely watched retatrutide spurred as much as 29% weight loss in a Phase 3 study, a finding that is “raising the bar ...

“Antinol Plus is a natural and effective way to relieve joint pain and support overall joint health,” shared Dr. Lisa Lippman ...